Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
INCB-099280 by Incyte for Colorectal Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
INCB-099280 by Incyte for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to...
INCB-099280 by Incyte for Gynecological Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Gynecological Cancer. According to GlobalData, Phase II...
INCB-099280 by Incyte for Metastatic Colorectal Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
INCB-099280 by Incyte for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...
INCB-099280 by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
INCB-099280 by Incyte for Renal Cell Carcinoma: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
INCB-099280 by Incyte for Metastatic Melanoma: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
INCB-099280 by Incyte for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...